|
1
|
FIGO Committee on Gynecologic Oncology.
FIGO staging for uterine sarcomas. Int J Gynaecol Obstet.
104:1792009. View Article : Google Scholar
|
|
2
|
McCluggage WG: Uterine carcinosarcomas
(malignant mixed Mullerian tumors) are metaplastic carcinomas. Int
J Gynecol Cancer. 12:687–690. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Arend R, Doneza JA and Wright J: Uterine
carcinosarcoma. Curr Opin Oncol. 23:531–536. 2011.PubMed/NCBI
|
|
4
|
Serkies K and Jassem J: Uterine
carcinosarcoma. Ginekol Pol. 83:609–612. 2012.(In Polish).
|
|
5
|
D’Angelo E and Prat J: Uterine sarcomas: a
review. Gynecol Oncol. 116:131–139. 2010.
|
|
6
|
McCluggage WG: Malignant biphasic uterine
tumours: carcinosarcomas or metaplastic carcinomas? J Clin Pathol.
55:321–325. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zaloudek C and Hendrickson MR: Mesenchymal
tumors of the uterus. Blaustein’s Pathology of the Female Genital
Tract. Kurman RJ: 5th edition. Springer; New York: pp. 561–615.
2002
|
|
8
|
Lopez-Garcia MA and Palacios J: Pathologic
and molecular features of uterine carcinosarcomas. Semin Diagn
Pathol. 27:274–286. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Abeln ECA, Smit VT, Wessels JW, de Leeuw
WJ, Cornelisse CJ and Fleuren GJ: Molecular genetic evidence for
the conversion hypothesis of the origin of malignant mixed
mullerian tumours. J Pathol. 183:424–431. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wada H, Enomoto T, Fujita M, et al:
Molecular evidence that most but not all carcinosarcomas of the
uterus are combination tumors. Cancer Res. 57:5379–5385.
1997.PubMed/NCBI
|
|
11
|
Jin Z, Ogata S, Tamura G, et al:
Carcinosarcomas (malignant mullerian mixed tumors) of the uterus
and ovary: a genetic study with special reference to histogenesis.
Int J Gynecol Pathol. 22:368–373. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Berchuck A, Kohler MF, Marks JR, Wiseman
R, Boyd J and Bast RC Jr: The p53 tumor suppressor gene frequently
is altered in gynecologic cancers. Am J Obstet Gynecol.
170:246–252. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Costa MJ, Vogelsan J and Young LJ:
p53 gene mutation in female genital tract carcinosarcomas
(malignant mixed mullerian tumors): a clinicopathologic study of 74
cases. Mod Pathol. 7:619–627. 1994.
|
|
14
|
Liu FS, Kohler MF, Marks JR, Bast RC Jr,
Boyd J and Berchuck A: Mutation and overexpression of the p53 tumor
suppressor gene frequently occurs in uterine and ovarian sarcomas.
Obstet Gynecol. 83:118–124. 1994.PubMed/NCBI
|
|
15
|
Soong R, Knowles S, Hammond IG, Michael C
and Iacopetta BJ: p53 protein overexpression and gene mutation in
mixed Mullerian tumors of the uterus. Cancer Detect Prev. 23:8–12.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Watanabe M, Shimizu K, Kato H, et al:
Carcinosarcoma of the uterus: immunohistochemical and genetic
analysis of clonality of one case. Gynecol Oncol. 82:563–567. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Semczuk A, Marzec B, Skomra D, et al:
Allelic loss at TP53 is not related to p53 protein
overexpression in primary human endometrial carcinomas. Oncology.
69:317–325. 2005.
|
|
18
|
de Jong RA, Nijman HW, Wijbrandi TF,
Reyners AK, Boezen HM and Hollema H: Molecular markers and clinical
behavior of uterine carcinosarcomas: focus on the epithelial tumor
component. Mod Pathol. 24:1368–1379. 2011.PubMed/NCBI
|
|
19
|
Yemelyanova A, Vang R, Kshirsagar M, et
al: Immunohistochemical staining pattern of p53 can serve as a
surrogate marker for TP53 mutations in ovarian carcinoma: an
immunohistochemical and nucleotide sequencing analysis. Mod Pathol.
24:1248–1253. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Blom R, Guerrieri C, Stâl O, Malmström H,
Sullivan S and Simonsen E: Malignant mixed Müllerian tumors of the
uterus: a clinicopathologic, DNA flow cytometric, p53, and mdm-2
analysis of 44 cases. Gynecol Oncol. 68:18–24. 1998.
|
|
21
|
Lee SJ, Kim HS, Kim HS, Chun YK, Hong SR
and Lee JH: Immunohistochemical study of DNA topoisomerase I, p53,
and Ki-67 in uterine carcinosarcomas. Hum Pathol. 38:1226–1231.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Semczuk A, Skomra D, Chyzynska M, Szewczuk
W, Olcha P and Korobowicz E: Immunohistochemical analysis of
carcinomatous and sarcomatous components in the uterine
carcinosarcoma: a case report. Pathol Res Pract. 204:203–207. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Scully RE, Bonfiglio TA, Kurman RJ,
Silverberg SG and Wilkinson EJ: Histological Typing of Female
Genital Tract Tumours. Springer-Verlag; Berlin, Heidelberg: 1994,
View Article : Google Scholar
|
|
24
|
Pecorelli S: Revised FIGO staging for
carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol
Obstet. 105:103–104. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Prat J: FIGO staging for uterine sarcomas.
Int J Gynaecol Obstet. 104:177–178. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
FIGO. Changes in gynecologic staging by
the International Federation of Gynecology and Obstetrics. Am J
Obstet Gynecol. 162:610–611. 1990.
|
|
27
|
Semczuk A, Skomra D, Cybulski M and
Jakowicki JA: Immunohistochemical analysis of MIB-1 proliferative
activity in human endometrial cancer. Correlation with
clinicopathological parameters, patient outcome, retinoblastoma
immunoreactivity and K-ras codon 12 point mutations.
Histochem J. 33:193–200. 2001. View Article : Google Scholar
|
|
28
|
Olcha P, Cybulski M, Skomra D, et al: The
pattern of p14ARF expression in primary and metastatic
human endometrial carcinomas: correlation with clinicopathological
features and TP53 pathway alterations. Int J Gynecol Cancer.
20:993–999. 2010.
|
|
29
|
Alkushi A, Lim P, Coldman A, Huntsman D,
Miller D and Gilks CB: Interpretation of p53 immunoreactivity in
endometrial carcinoma: establishing a clinically relevant cut-off
level. Int J Gynecol Pathol. 23:129–137. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Iwasa Y, Haga H, Konishi I, et al:
Prognostic factors in uterine carcinosarcoma: a clinicopathologic
study of 25 patients. Cancer. 82:512–519. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bodner-Adler B, Bodner K, Obermair A, et
al: Prognostic parameters in carcinosarcomas of the uterus: a
clinico-pathologic study. Anticancer Res. 21:3069–3074.
2001.PubMed/NCBI
|
|
32
|
Amant F, Cadron I, Fuso L, et al:
Endometrial carcinosarcomas have a different prognosis and pattern
of spread compared to high-risk epithelial endometrial cancer.
Gynecol Oncol. 98:274–280. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kounelis S, Jones MW, Papadaki H, Bakker
A, Swalsky P and Finkelstein SD: Carcinosarcomas (malignant mixed
mullerian tumors) of the female genital tract: comparative
molecular analysis of epithelial and mesenchymal components. Hum
Pathol. 29:82–87. 1998. View Article : Google Scholar
|
|
34
|
Kanthan R, Senger J-LB and Diudea D:
Malignant mixed Mullerian tumors of the uterus: histopathological
evaluation of cell cycle and apoptotic regulatory proteins. World J
Surg Oncol. 8:602010. View Article : Google Scholar
|
|
35
|
Mayall F, Rutty K, Campbell F and Goddard
H: p53 immunostaining suggests that uterine carcinosarcomas are
monoclonal. Histopathology. 24:211–214. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Swisher EM, Gown AM, Skelly M, et al: The
expression of epidermal growth factor receptor, HER-2/Neu,
p53, and Ki-67 antigen in uterine malignant mixed mesodermal tumors
and adenosarcoma. Gynecol Oncol. 60:81–88. 1996.PubMed/NCBI
|
|
37
|
Sherman ME, Bur ME and Kurman RJ: p53 in
endometrial cancer and its putative precursors: evidence for
diverse pathways of tumorigenesis. Hum Pathol. 26:1268–1274. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Petitjean A, Achatz MI, Borresen-Dale AL,
Hainaut P and Olivier M: TP53 mutations in human cancers:
functional selection and impact on cancer prognosis and outcomes.
Oncogene. 26:2157–2165. 2007. View Article : Google Scholar
|
|
39
|
Fujii H, Yoshida M, Gong ZX, et al:
Frequent genetic heterogeneity in the clonal evolution of
gynecological carcinosarcoma and its influence on phenotypic
diversity. Cancer Res. 60:114–120. 2000.PubMed/NCBI
|
|
40
|
Szukala SA, Marks JR, Burchette JL,
Elbendary AA and Krigman HR: Co-expression of p53 by epithelial and
stromal elements in carcinosarcoma of the female genital tract: an
immunohistochemical study of 19 cases. Int J Gynecol Cancer.
9:131–136. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Taylor NP, Zighelboim I, Huettner PC, et
al: DNA mismatch repair and TP53 defects are early events in
uterine carcinosarcoma tumorigenesis. Mod Pathol. 19:1333–1338.
2006.PubMed/NCBI
|
|
42
|
Yuan Y, Kim WH, Han HS, et al:
Establishment and characterization of cell lines derived from
uterine malignant mixed Müllerian tumor. Gynecol Oncol. 66:464–474.
1997.PubMed/NCBI
|
|
43
|
Hoon DS, Kitago M, Kim J, et al: Molecular
mechanisms of metastasis. Cancer Metastasis Rev. 25:203–220. 2006.
View Article : Google Scholar
|
|
44
|
Sreenan JJ and Hart WR: Carcinosarcomas of
the female genital tract. A pathologic study of 29 metastatic
tumors: further evidence for the dominant role of the epithelial
component and the conversion theory of histogenesis. Am J Surg
Pathol. 19:666–674. 1995. View Article : Google Scholar
|
|
45
|
Jeczen R, Skomra D, Cybulski M, et al:
P53/MDM2 overexpression in metastatic endometrial cancer:
correlation with clinicopathological features and patient outcome.
Clin Exp Metastasis. 24:503–511. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Semczuk A, Schneider-Stock R and Szewczuk
W: Prevalence of allelic loss at TP53 in endometrial
carcinomas. Oncology. 78:220–228. 2010. View Article : Google Scholar
|
|
47
|
Nicòtina PA, Ferlazzo G and Vincelli AM:
Proliferation indices and p53-immunocytochemistry in uterine mixed
mullerian tumors. Histol Histopathol. 12:967–972. 1997.PubMed/NCBI
|
|
48
|
Abargel A, Avinoach I, Kravtsov V, Boaz M,
Glezerman M and Menczer J: Expression of p27 and p53: comparative
analysis of uterine carcinosarcoma and endometrial carcinoma. Int J
Gynecol Cancer. 14:354–359. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Buza N and Tavassoli FA: Comparative
analysis of P16 and P53 expression in uterine malignant mixed
mullerian tumors. Int J Gynecol Pathol. 28:514–521. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Koivisto-Korander R, Butzow R, Koivisto AM
and Leminen A: Immunohistochemical studies on uterine
carcinosarcoma, leiomyosarcoma, and endometrial stromal sarcoma:
expression and prognostic importance of ten different markers.
Tumour Biol. 32:451–459. 2011. View Article : Google Scholar
|
